Header01-REBRAND_MENARINISILICONBIOSYSTEMS

 

Press Releases

11/30/2021

New CELLSEARCH® Circulating Multiple Myeloma Test now available to help community physicians optimize patient care


As the market leader in cell-based liquid biopsies, Menarini Silicon Biosystems is offering community hematology-oncologists an opportunity to have patient blood samples sent to a US centralized laboratory where its CELLSEARCH® technology can enumerate Circulating Multiple Myeloma Cells (CMMCs) for non-invasive monitoring of disease

continue →

Topics: CELLSEARCH, Liquid biopsy, Multiple myeloma, CLIA Lab, LDT

06/7/2021

Menarini’s CELLSEARCH® Circulating Endothelial Cells assay to monitor systemic sclerosis in clinical research studies: new data presented at the 2021 EULAR Congress


This non-invasive test leverages the Gold Standard CELLSEARCH platform to enumerate Circulating Endothelial Cells from blood and may provide novel and valuable information on systemic sclerosis disease. The test is available to all professionals as a lab service in Europe and the US.

continue →

Topics: CELLSEARCH, CECs, Circulating Endothelial Cells, Lab Services, Systemic Sclerosis

03/31/2021

Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies


The new test, available as a Lab Service throughout Europe and US, leverages the Gold Standard CELLSEARCH platform to enumerate Circulating Multiple Myeloma Cells from blood and offers real-time standardized monitoring of multiple myeloma in clinical research studies.

continue →

Topics: CELLSEARCH, Multiple myeloma, CMMCs, Lab Services

02/16/2021

Menarini Silicon Biosystems announces launch of CellMag™ product line offering affordable Gold Standard Circulating Tumor Cells capture


CELLMAG – a cost effective, manual and simple approach for the enrichment and staining of extremely rare cells from blood

continue →

Topics: CTCs, CELLSEARCH, Liquid biopsy, Blood Enrichment, CellMag

12/10/2020

DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor


Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome

continue →

Topics: CELLSEARCH, metastatic breast cancer, HER2, San Antonio Breast Cancer Symposium, CTC phenotyping

12/9/2020

New Global Pooled Analysis Supports Clinical Utility of Circulating Tumor Cell Count for Early Monitoring of Metastatic Breast Cancer


Robust pooled analysis demonstrating how CTC count may help to optimize treatment choices

continue →

Topics: CELLSEARCH, metastatic breast cancer, global pooled analysis, San Antonio Breast Cancer Symposium

11/9/2020

New Research Study Supports Clinical Utility of Circulating Tumor Cell Count for Metastatic Breast Cancer


First randomized clinical trial demonstrating that CTC count may help personalize treatment choices

continue →

Topics: CELLSEARCH, metastatic breast cancer, STIC

08/4/2020

Two Studies Presented at AACR Meeting Deepen Understanding Of Cancer Mechanisms

Researchers Use Menarini’s Liquid Biopsy Technology to Find Genetic Alterations in Cancer Cells that May Improve Prognosis and Treatment

continue →

Topics: CELLSEARCH, metastatic breast cancer, Multiple myeloma, HER2, AACR

07/13/2020

Menarini Silicon Biosystems Partners with OpGen to Broaden Distribution of CELLSEARCH Platform in North America

Strategic partnership will focus on commercializing CELLSEARCH platform for
COVID-19 related use cases, along with other COVID-19 related products

continue →

Topics: CELLSEARCH, COVID-19, OpGEN

06/10/2020

New ASCO Studies Offer Evidence for Use of Circulating Tumor Cells as a Prognostic Biomarker for Advanced Prostate and Breast Cancer

Results from prospective trials show a "clear prognostic value" for CTC counts

continue →

Topics: CTCs, CELLSEARCH, metastatic breast cancer, prostate cancer, ASCO